DOJ in­ves­ti­gat­ing Bausch Health over plaque pso­ri­a­sis drug mar­ket­ing — re­port

Just a few weeks af­ter Bausch Health ran afoul of the FDA’s drug mar­ket­ing po­lice, a new re­port has emerged that the com­pa­ny has been un­der in­ves­ti­ga­tion by the De­part­ment of Jus­tice since at least last June.

STAT News re­port­ed Bausch cir­cu­lat­ed doc­u­ments among its le­gal team on June 14, 2021, out­lin­ing its strat­e­gy to com­ply with the DOJ’s re­quest. The probe, known as a civ­il in­ves­tiga­tive de­mand, aims to look at whether Bausch pro­mot­ed three plaque pso­ri­a­sis drugs — as well as a fun­gal treat­ment — in ways not in­tend­ed for use.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER